Cost-effectiveness of atazanavir/ritonavir compared with lopinavir/ritonavir in treatment-naïïve human immunodeficiency virus-1 patients in Sweden

By Thuresson Per-Olof   Heeg Bart   Lescrauwaet Benedicte   Sennfäält Karin   Alaeus Annette   Neubauer Aljoscha  

Scandinavian Journal of Infectious Diseases, Vol. 43, Iss. 4, 2011-04 ,pp. : 304-312

Informa Healthcare

Access to resources Recommend Favorite

Randomized trial of interferon‐ and ribavirin‐free ombitasvir/paritaprevir/ritonavir in treatment‐experienced hepatitis C virus–infected patients

By  

HEPATOLOGY, Vol. 61, Iss. 5, 2015-05 ,pp. : 1523-1532

John Wiley & Sons Inc

Access to resources Recommend Favorite

Comparison of atazanavir with lopinavir/ritonavir in patients with prior protease inhibitor failure: a randomized multinational trial

By Cohen C.   Nieto-Cisneros L.   Zala C.   Fessel W. J.   Gonzalez-Garcia J.   Gladysz A.   McGovern R.   Adler E.   McLaren C.    

Current Medical Research and Opinion, Vol. 21, Iss. 10, 2005-10 ,pp. : 1683-1692

Informa Healthcare

Access to resources Recommend Favorite

Use of the Protease Inhibitor Saquinavir Hard Gel in Human Immunodeficiency Virus-infected Patients in the Early Period of Highly Active Antiretroviral Therapy: Does it Affect Long-term Treatment Outcome?

By Jensen-fangel Søren   Pedersen Court   Nielsen Henrik   Tauris Palle   Møller Axel   Sørensen Henrik Toft   Obel Niels  

Scandinavian Journal of Infectious Diseases, Vol. 35, Iss. 10, 2003-10 ,pp. : 743-749

Informa Healthcare

Access to resources Recommend Favorite

Randomized phase 3 trial of ombitasvir/paritaprevir/ritonavir for hepatitis C virus genotype 1b–infected Japanese patients with or without cirrhosis

By  

HEPATOLOGY, Vol. 270-9139, Iss. 4, 2015-10 ,pp. : 1037-1046

John Wiley & Sons Inc

Access to resources Recommend Favorite